Level Wealth Management LLC Acquires Shares of 12,176 Pfizer Inc. (NYSE:PFE)

Level Wealth Management LLC bought a new position in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 12,176 shares of the biopharmaceutical company’s stock, valued at approximately $323,000.

Several other institutional investors also recently modified their holdings of PFE. WFA Asset Management Corp grew its holdings in Pfizer by 778.8% in the fourth quarter. WFA Asset Management Corp now owns 1,696 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,503 shares during the period. Golden State Equity Partners boosted its position in shares of Pfizer by 922.9% in the 4th quarter. Golden State Equity Partners now owns 18,188 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 16,410 shares in the last quarter. Avantra Family Wealth Inc. purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $398,000. SYM FINANCIAL Corp raised its stake in Pfizer by 209.0% during the fourth quarter. SYM FINANCIAL Corp now owns 21,483 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 14,531 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in Pfizer by 2.3% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 158,076 shares of the biopharmaceutical company’s stock worth $4,194,000 after acquiring an additional 3,557 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Guggenheim cut their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Down 1.5 %

Shares of NYSE:PFE opened at $26.51 on Friday. The stock’s 50-day simple moving average is $26.27 and its two-hundred day simple moving average is $27.86. The stock has a market capitalization of $150.20 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. Pfizer’s dividend payout ratio (DPR) is presently 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.